% | $
Quotes you view appear here for quick access.

Nanophase Technologies Corp. Message Board

jprazsky 4 posts  |  Last Activity: Jun 27, 2016 9:52 AM Member since: Jan 4, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Jeffries breakout session

    by ofjames Jun 18, 2016 8:23 PM
    jprazsky jprazsky Jun 27, 2016 9:52 AM Flag

    You can also see it from a different perspective... The 214 does not do much as a single agent ( I would be surprized if nothing leaks out in case of some great results) so they take another one from the bag to calm down investors with another hope....

  • You may have noticed that there was a vote on May 18th... and this is the result...

    So Starboard does not have the votes do induce any serious changes, but they can exchange their shares for the HZNP 1:1 if they want to loose 20% of the value....

    Shares Voted For Shares Voted Against Abstain Broker Non-Votes

    Peter D. Staple 36,175,602 6,143,524 85,330 10,235,351

    Karen A. Dawes 36,169,133 6,147,100 88,223 10,235,351

    Louis J. Lavigne, Jr. 36,201,282 6,095,063 108,111 10,235,351

    Samuel R. Saks, M.D. 36,170,282 6,148,391 85,783 10,235,351

    James A. Schoeneck 36,495,032 5,851,267 58,157 10,235,351

    David B. Zenoff, D.B.A. 36,079,759 6,240,620 84,077 10,235,351

  • Reply to

    MD Anderson Clinical Trials

    by gladpick May 23, 2016 4:12 PM
    jprazsky jprazsky May 24, 2016 7:57 AM Flag

    The trial started also at Yale Kidney, Lung, Melanoma, skin, Phase I

    It is listed at their web page

    The NKTR-214 clinical study is being conducted initially at two primary investigator sites: MD Anderson Cancer Center under Drs. Patrick Hwu and Adi Diab; and Yale Cancer Center, under Drs. Mario Sznol and Michael Hurwitz.

  • After my long time experience with NKTR, I would also consider the possibility, that 214 in the phase 1 did not show any significant effect on the disease, while it was safe. So they did not disclose anything and are waiting for the miracle/good news from the combination treatment under the phase 2. It is always fun to go through all the old NKTR presentations on my PC, with all the great news from HR just imminent for the next Q... If the insiders continue to sell into summer, then it would be probably time to sell...